Single-Dose Sufentanil NanoTab: Phase III started

AcelRx began the open-label, U.S. Phase III SAP302 trial to evaluate a single dose of 30 ug sublingual ARX-04 in about 40 adult emergency room patients. Earlier this year, the company received a $17 m...